Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
Rujuta Saksena, Serena T WongThe Cancer Institute of New Jersey, New Brunswick, NJ, USAAbstract: The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promote...
Guardado en:
Autores principales: | Saksena R, Wong ST |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0b912949152243b5b0031d7cb067a685 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo KA, et al.
Publicado: (2014) -
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Andrea Gombos, et al.
Publicado: (2021) -
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
por: Criscitiello C, et al.
Publicado: (2018) -
Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger K, et al.
Publicado: (2015) -
Potential clinical applications of halichondrins in breast cancer and other neoplasms
por: Ortega V, et al.
Publicado: (2012)